Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 3Recruiting 2

Sponsor Class

NETWORK 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Leukemia, Myeloid, Acute 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Myelodysplastic Syndromes 48Multiple Myeloma 38Lymphoma 37Leukemia 35Lymphoma, Non-Hodgkin 29Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 24Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Hematologic Neoplasms 18Lymphoma, Large B-Cell, Diffuse 16Primary Myelofibrosis 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Neoplasms, Plasma Cell 10Myeloproliferative Disorders 10Graft vs Host Disease 10Lymphoma, Follicular 9Leukemia, Biphenotypic, Acute 9Burkitt Lymphoma 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Juvenile 7Breast Neoplasms 6Rhabdoid Tumor 5Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, B-Cell, Marginal Zone 5

Interventions

Cyclophosphamide 8dinutuximab 7Magnetic Resonance Spectroscopy 7Topotecan 6Doxorubicin 6sargramostim 5Vincristine 5Stem Cell Transplantation 5Radiation 5Platinum 5Melphalan 5Isotretinoin 5Colony-Stimulating Factors 5Cisplatin 5Biopsy 51,2-diaminocyclohexaneplatinum II citrate 5Temozolomide 4Specimen Handling 4Irinotecan 4Etoposide 4Congresses as Topic 4Carboplatin 4Thiotepa 3Busulfan 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2temsirolimus 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Ganglioneuroblastoma × Stem Cell Transplantation × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01175356 2026-01-23

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Children's Oncology Group

Phase 1 Completed
99 enrolled 11 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01798004 2024-07-15

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Children's Oncology Group

Phase 1 Completed
150 enrolled 9 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡